Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results
Portfolio Pulse from
Nyxoah SA reported its financial and operating results for Q4 and FY 2024, with a focus on its upcoming U.S. commercial launch in March 2025. The FDA PMA application review is nearing completion.
March 13, 2025 | 6:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nyxoah SA reported its Q4 and FY 2024 financial results, highlighting a revenue of €1 million for Q4. The company is nearing the completion of its FDA PMA application review, positioning it for a U.S. commercial launch in March 2025.
The nearing completion of the FDA PMA application review and the planned U.S. commercial launch in March 2025 are significant milestones for Nyxoah. These developments are likely to positively impact the stock price as they indicate progress towards market expansion and potential revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100